UIA
PTCT icon

Ulland Investment Advisors’s PTC Therapeutics PTCT Stock Holding History

Ulland Investment Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$5K – 237
2025
Q2 		$5K Buy
+100
New +$4.75K ﹤0.01% 187

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ulland Investment Advisors's PTCT Position: Q3 2025 in Review

Ulland Investment Advisors sold out of PTC Therapeutics (PTCT) in Q3 2025, closing a stake of 100 shares — an estimated $5K sold.

Ulland Investment Advisors first reported a position in PTCT in Q2 2025 and held it in 1 quarter. The position peaked at $5K in Q2 2025. 293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • Ulland Investment Advisors reported no remaining PTC Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Ulland Investment Advisors sold 100 PTC Therapeutics shares in Q3 2025, an estimated $5K.
  • Ulland Investment Advisors first reported a position in PTC Therapeutics in Q2 2025 and held it in 1 quarter.
  • Ulland Investment Advisors's PTC Therapeutics position peaked at $5K in Q2 2025.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on Ulland Investment Advisors's 13F filing for Q3 2025, filed 13 Nov 2025.